Arabic Arabic English English French French German German
dark

Study finds hydroxychloroquine delays disability for least treatable form of multiple sclerosis

A University of Calgary study has found promising results for the generic drug hydroxychloroquine when used to treat the evolution of disability of primary progressive multiple sclerosis (MS), the least treatable form of the autoimmune disease. MS affects about 90,000 Canadians with about 15 percent of those diagnosed with primary progressive MS, one of the highest rates in the world. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

This Healthcare Meme Made Me LOL

Next Post

WHO recommends two new drugs to treat patients with COVID-19

Related Posts
Total
0
Share